Bausch Health Cos Inc. $BHC Shares Sold by Compass Rose Asset Management LP

Compass Rose Asset Management LP cut its stake in shares of Bausch Health Cos Inc. (NYSE:BHC) by 50.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 250,000 shares of the company’s stock after selling 250,000 shares during the period. Bausch Health Cos accounts for approximately 0.3% of Compass Rose Asset Management LP’s holdings, making the stock its 14th biggest holding. Compass Rose Asset Management LP owned approximately 0.07% of Bausch Health Cos worth $1,612,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in BHC. Goldentree Asset Management LP boosted its holdings in Bausch Health Cos by 13.2% in the second quarter. Goldentree Asset Management LP now owns 34,254,889 shares of the company’s stock valued at $227,848,000 after acquiring an additional 4,004,889 shares during the last quarter. Paulson & CO. Inc. increased its stake in Bausch Health Cos by 24.0% during the second quarter. Paulson & CO. Inc. now owns 32,791,702 shares of the company’s stock worth $218,393,000 after acquiring an additional 6,352,667 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Bausch Health Cos by 4.0% in the 3rd quarter. Vanguard Group Inc. now owns 12,241,072 shares of the company’s stock worth $78,808,000 after purchasing an additional 470,968 shares during the period. Maple Rock Capital Partners Inc. lifted its stake in shares of Bausch Health Cos by 14.9% in the 2nd quarter. Maple Rock Capital Partners Inc. now owns 7,808,487 shares of the company’s stock valued at $52,005,000 after purchasing an additional 1,010,987 shares in the last quarter. Finally, SG Americas Securities LLC lifted its stake in shares of Bausch Health Cos by 114.4% in the 2nd quarter. SG Americas Securities LLC now owns 6,152,986 shares of the company’s stock valued at $40,979,000 after purchasing an additional 3,282,684 shares in the last quarter. 78.65% of the stock is currently owned by institutional investors and hedge funds.

More Bausch Health Cos News

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Zacks bumped some near‑term/near‑term‑adjacent forecasts — including FY‑2026 (to $3.92 EPS), Q4‑2026 (to $1.10), Q1‑2027 (to $0.82) and Q3‑2027 (to $1.12) — suggesting parts of the company’s near‑term earnings outlook improved. Zacks revisions (summary)
• Neutral Sentiment: Zacks published an FY‑2028 estimate ($3.36 EPS) which provides a longer‑horizon view but is farther out and less likely to move the stock materially in the short term. FY‑2028 estimate
• Negative Sentiment: Zacks trimmed a number of core near‑term forecasts: Q2‑2027 EPS was cut notably (from $0.96 to $0.89) and Zacks reduced its FY‑2027 outlook (to $3.79 from $3.85), along with cuts to several quarterly estimates — a driver of downward earnings expectations and selling pressure. Zacks cuts (summary)
• Negative Sentiment: The Portnoy Law Firm has opened an investigation into Bausch + Lomb Corporation (BLCO) for possible securities fraud; while that probe targets BLCO, market participants may view it as a reputational/legal overhang for companies carrying the Bausch name or related assets, increasing risk sentiment. Bausch + Lomb investigated (GlobeNewswire)

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on BHC shares. Wall Street Zen downgraded shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 15th. Raymond James Financial reaffirmed a “market perform” rating on shares of Bausch Health Cos in a research report on Monday, January 26th. Weiss Ratings downgraded shares of Bausch Health Cos from a “hold (c)” rating to a “sell (d+)” rating in a research note on Thursday, February 19th. Truist Financial increased their price objective on shares of Bausch Health Cos from $7.00 to $8.00 and gave the stock a “hold” rating in a research report on Wednesday, January 7th. Finally, Barclays cut their target price on shares of Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 25th. Four analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus price target of $8.33.

Bausch Health Cos Stock Performance

Shares of NYSE:BHC opened at $4.97 on Friday. The company has a market cap of $1.85 billion, a P/E ratio of 11.82 and a beta of 0.37. The company has a debt-to-equity ratio of 54.68, a quick ratio of 1.08 and a current ratio of 1.47. Bausch Health Cos Inc. has a one year low of $4.25 and a one year high of $8.69. The business’s 50-day simple moving average is $6.20 and its 200 day simple moving average is $6.53.

Bausch Health Cos (NYSE:BHC) last released its quarterly earnings results on Wednesday, February 18th. The company reported $1.08 EPS for the quarter, missing the consensus estimate of $1.21 by ($0.13). Bausch Health Cos had a return on equity of 875.00% and a net margin of 1.53%.The company had revenue of $2.78 billion for the quarter, compared to analyst estimates of $2.71 billion. On average, sell-side analysts forecast that Bausch Health Cos Inc. will post 4.41 earnings per share for the current fiscal year.

Bausch Health Cos Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.